Business Context and Reporting Period
This Form 8-K is filed by Aerpio Pharmaceuticals, Inc. (not Whitehawk Therapeutics, Inc.) on August 14, 2018. The filing serves to announce the company's financial results for the quarter ended June 30, 2018. The detailed results are contained in a press release furnished as Exhibit 99.1.
Key Financial Metrics
The filing text provided does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being detailed in the attached press release (Exhibit 99.1), which is not included in the source text.
Material Changes
No material changes versus the prior comparable period are described in the text of this Form 8-K. The document solely acts as a notification that the Q2 2018 results have been announced.
Guidance, Outlook, and Risks
The filing includes a standard disclaimer stating that the information furnished in this report and Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and shall not be incorporated by reference into other filings unless expressly stated. No specific guidance, outlook, or risk factors are detailed in the provided text.
Investor Verification Checklist
- Verify the specific financial figures (revenue, net loss, cash position) by reviewing the attached Exhibit 99.1 (Press Release), as they are absent from the 8-K text.
- Confirm the registrant name is Aerpio Pharmaceuticals, Inc., noting the discrepancy with the metadata field "Whitehawk Therapeutics, Inc."
- Review the press release for any updates on clinical trial progress or regulatory milestones, which are typical for this sector but not listed in the 8-K summary.